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Biocompatibility (i.e., the quality of not having toxic or injurious effects on biological systems) requirements for
single-use products in the biotechnology industry can vary depending on point of use. For example, single-use
syringes are considered a combination medical device and thus require assessment according to the ISO 10993
standards with test ranging from acute systemic toxicity to genotoxicity to sensitization. Processing equipment
(e.g., reaction vessels, tubing, filters, chromatography columns) in contrast, generally requires a USP Class VI
designation (a battery of in vivo tests consisting of acute systemic toxicity, intracutaneous reactivity, and muscle
implantation) with rigorous requirements for leachates. The USP Class VI Plastic test was developed to test drug
containers and is designed to evaluate the biological reactivity of various types of plastic materials in vivo, while
the ISO 10993 tests addresses biological hazards of medical devices (and their materials of construction) based
upon duration and route of exposure. As the use of disposables in biopharma production continues to increase, a
primary focus of these new, and often cutting-edge, products is patient and drug safety. During their life-cycle
(i.e., manufacture to end-use) single-use products in the biotechnology industry come in contact with processing
equipment, packaging components, and delivery systems that might transfer small amounts of chemicals that can
negatively impact cell growth and product titers, or even compromise drug safety. It is thus critical that both the
materials of construction and the product contact surfaces used during production are appropriate for the intended
end-use of the single-use device. Specific examples of material selection, biological and chemical (i.e.,
extractable/leachable) study selection, and subsequent risk assessments will be presented and discussed.

